AAO News
The latest clinical breakthroughs, practice management updates, and national advocacy alerts directly from the American Academy of Ophthalmology.
A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration
To assess the safety and tolerability of E10030 (Fovista; Ophthotech, New York, NY), a platelet-derived growth factor (PDGF) antagonist, when administered in combination with an anti-vascular endothelial growth factor (VEGF) agent, ranibizumab (Lucentis; Genentech, South San Francisco, CA) 0.5 mg, by intravitreal injection in participants with neovascular age-related macular degeneration (NVAMD).
Powered by Versicherungsvergleich
Our Industry Partners
Empowering Excellence in Ophthalmology
We extend our deepest gratitude to our Platinum, Gold, and Silver partners. Your generous support fuels our mission to advance medical education, advocate for patient safety, and foster breakthrough innovations across West Virginia.
West Virginia Academy of Eye Physicians and Surgeons — advancing quality eye care through education, advocacy, and community awareness.
About
Resources
Advocacy